2015-05-28 13:53:46 UTC

FDA Approves New IBS-D Therapies

May 28, 2015

Two new treatments have received FDA approval to treat adults with diarrhea-predominant IBS.

The FDA has approved two new treatments for IBS with diarrhea in adult men and women — Viberzi (eluxadoline) and Xifaxan (rifaximin). The products are manufactured by two different companies.

Viberzi, which contains a new active ingredient, is taken orally twice daily with food. Viberzi activates receptors in the nervous system that can lessen bowel contractions. Viberzi is intended to treat adults with IBS-D.

Xifaxan can be taken orally three times a day for 14 days, for the treatment of abdominal pain and diarrhea in patients with IBS-D. Patients who experience a recurrence of symptoms can be retreated with a 14-day treatment course, up to two times. Xifaxan, an antibiotic derived from rifampin, was previously approved as treatment for travelers’ diarrhea caused-by E. coli and for reducing the risk of recurring overt hepatic encephalopathy, the changes in brain function that occur when the liver is unable to remove toxins from the blood. The exact mechanism of action of Xifaxan for treatment of IBS-D is not known, but is thought to be related to changes in the bacterial content of the gastrointestinal tract.

More on Irritable Bowel Syndrome

2018 AGA Postgraduate Course

June 2, 2018

Secure your spot for this clinically focused, multi-topic course that offers immediately applicable information. Held in conjunction with DDW®. Save $75 when you register by April 18.

FDA Announces GREAT 5 Public Workshop

Feb. 16, 2018

The three-day public workshop will focus on alcoholic hepatitis and liver disease, and pediatric IBS and functional constipation.

Save the Date: 2018 AGA Postgraduate Course

Jan. 11, 2018

This year’s course will take place on June 2 and 3, 2018, in Washington, D.C.